Impact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma

Journal of Thoracic Disease 2023 December 30 [Link] Douglas Z Liou, Yoyo Wang, Prasha Bhandari, Joseph B Shrager, Natalie S Lui, Leah M Backhus, Mark F Berry Abstract Background: Modern treatment guidelines recommend multimodal therapy with at least chemotherapy and surgery for patients with potentially resectable epithelioid mesothelioma. This study evaluated guideline compliance for patients…

Read More

Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort

ERJ Open Research 2023 December 27 [Link] Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby Abstract Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma…

Read More

Extensive Skeletal Muscle Metastases in Malignant Pleural Mesothelioma Detected by FDG PET/CT

World Journal of Nuclear Medicine 2023 December 4 [Link] Mustafa Yilmaz, Ozan Kandemir, Ediz Tutar Abstract Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from pleural mesothelial cells. Distant skeletal muscle metastasis is rare in MPM. A 54-year-old woman was diagnosed with epithelioid MPM and treated with surgery, chemotherapy, and radiotherapy 2…

Read More

Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…

Read More

Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series

Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…

Read More

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299

JTO Clinical and Research Reports 2023 October 12 [Link] Arkadiusz Z Dudek 1 2, Min X Xi 1, Katherine A Scilla 3, Hirva Mamdani 4, Benjamin C Creelan 5, Andreas Saltos 5, Tawee Tanvetyanon 5, Alberto Chiappori Abstract Introduction: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent…

Read More

Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma

International Journal of Surgical Protocols 2023 September 26 [Link] Paul H Sugarbaker Abstract Background: Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as…

Read More

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers

Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually…

Read More

Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology

European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…

Read More